Clinical Trial Update: Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma [NA]

View source ↗

Summary

A clinical trial evaluating ponatinib for FGFR mutation-positive recurrent or persistent endometrial cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Ponatinib (Iclusig) (ponatinib)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Endometrial Neoplasms | NA | Status: WITHDRAWN